摩罗丹联合奥美拉唑治疗对慢性胃炎患者疗效及炎症因子、胃蛋白酶原水平的影响

Effects of Morodan combined with Omeprazole on curative efficacy,inflammatory factor and pepsinogen levels in the patients with chronic gastritis

目的探讨摩罗丹联合奥美拉唑治疗对慢性胃炎患者疗效及炎症因子、胃蛋白酶原水平的影响。方法将2016年9月至2018年9月在阳新县人民医院治疗的101例慢性胃炎患者按照给药方式分为对照组49例,治疗组52例。对照组口服奥美拉唑肠溶胶囊,治疗组在对照组基础上口服摩罗丹。分析2组疗效和炎症因子、胃蛋白酶原亚群水平,并统计不良反应发生率。结果治疗前,2组炎症因子及胃蛋白酶原亚群水平差异无统计学意义(P>0.05)。治疗后,2组炎症因子及胃蛋白酶原II(PGⅡ)水平较治疗前显著降低(P<0.05),胃蛋白酶原I(PGⅠ)水平及胃蛋白酶原I/胃蛋白酶原II(PGⅠ/PGⅡ)比值较治疗前显著升高(P<0.05);且治疗组炎症因子及PGⅡ水平明显低于对照组(P<0.05),总有效率、PGⅠ水平及PGⅠ/PGⅡ比值明显高于对照组(P<0.05);2组不良反应发生率差异无统计学意义(P>0.05)。结论摩罗丹联合奥美拉唑治疗能显著提高慢性胃炎患者疗效,缓解炎症反应,改善胃黏膜腺体功能,具有一定的临床推广应用价值。

Objective To investigate the effects of Morodan combined with Omeprazole on curative efficacy,inflammatory factors and pepsinogen levels in the patients with chronic gastritis.Methods One hundred and one patients with chronic gastritis ad⁃mitted into hospital from September 2016 to September 2018 were divided into the control group(n=49)and the treatment group(n=52)by different medication methods.The control group simply took Omeprazole enteric⁃coated capsules orally,while the treatment group received Morodan on the basis of the treatment in the control group.The curative effect,inflammatory factor and pepsinogen sub⁃group levels of the two groups were observed and the rate of adverse reactions was also analyzed.Results Before treatment,no statisti⁃cal significance could be seen in inflammatory factor and pepsinogen subgroup levels,when comparisons were made between the 2 groups(P>0.05).After treatment,the levels of inflammatory factors and pepsinogen II(PG II)in both groups significantly de⁃creased,as compared with those before treatment(P<0.05),and the levels of pepsinogen I(PG I)and the ratio of pepsinogen I to pepsinogen II(PG I/PG II)were significantly higher than those before treatment(P<0.05).The levels of inflammatory factor and PG II in the treatment group were significantly lower than those of the control group(P<0.05).Total effective rate,PG I level and the ra⁃tio of PG I/PG II in the treatment group were significantly higher than those of the control group(P<0.05).However,there was no statistical significance in the rate of adverse reactions,when comparisons were made between the 2 groups(P>0.05).Conclusion Morodan combined with Omeprazole could significantly improve the curative effect of the patients with chronic gastritis,alleviate inflammation and improve glandular function of gastric mucosa.Therefore,it is worth further clinical extension.